| 8.75 -0.28 (-3.1%) | 07-31 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 12.98 |
1-year : | 14.75 |
| Resists | First : | 11.11 |
Second : | 12.63 |
| Pivot price | 10.98 |
|||
| Supports | First : | 8.66 |
Second : | 7.2 |
| MAs | MA(5) : | 10.63 |
MA(20) : | 11.22 |
| MA(100) : | 11.25 |
MA(250) : | 12.39 |
|
| MACD | MACD : | -0.3 |
Signal : | 0 |
| %K %D | K(14,3) : | 21.5 |
D(3) : | 39.3 |
| RSI | RSI(14): 31.8 |
|||
| 52-week | High : | 18.3 | Low : | 8.02 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ PHAT ] has closed below the lower bollinger band by 10.4%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ PHAT ] is to continue within current trading range. It is unclear right now based on current values. 46% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 9.47 - 9.54 | 9.54 - 9.59 |
| Low: | 8.5 - 8.59 | 8.59 - 8.65 |
| Close: | 8.76 - 8.87 | 8.87 - 8.96 |
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.
Fri, 31 Jul 2026
Phathom Pharmaceuticals (PHAT) Stock Slides Despite Cash Profit Breakthrough - simplywall.st
Fri, 31 Jul 2026
PHAT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Phathom Pharmaceuticals - Morningstar
Fri, 31 Jul 2026
Phathom Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Thu, 30 Jul 2026
PHAT Stock Clocks Worst Day In Over 1.5 Years — What Sparked The Selloff? - TradingView
Thu, 30 Jul 2026
Is Phathom Pharmaceuticals Inc (PHAT) Set for Growth After Q2 Ea - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 80 (M) |
| Shares Float | 64 (M) |
| Held by Insiders | 4.7 (%) |
| Held by Institutions | 88.9 (%) |
| Shares Short | 12,120 (K) |
| Shares Short P.Month | 11,160 (K) |
| EPS | -2.09 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -4.24 |
| Profit Margin | -76.8 % |
| Operating Margin | -26.6 % |
| Return on Assets (ttm) | -20.2 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 104.4 % |
| Gross Profit (p.s.) | 2.18 |
| Sales Per Share | 2.56 |
| EBITDA (p.s.) | -1.21 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -97 (M) |
| Levered Free Cash Flow | -78 (M) |
| PE Ratio | -4.25 |
| PEG Ratio | 0 |
| Price to Book value | -2.1 |
| Price to Sales | 3.45 |
| Price to Cash Flow | -7.27 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|